Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propiolactone (specifically beta-propiolactone) is a small molecule organic compound belonging to the lactones with a four-membered ring structure. It is a colorless liquid with a slightly sweetish and pungent odor. Propiolactone acts as an alkylating agent that reacts readily with nucleophiles via ring-opening reactions. Historically used as an intermediate in the synthesis of acrylic acid and esters and as a sterilant/disinfectant for blood plasma, vaccines, tissue grafts, surgical instruments and enzymes due to its potent sporicidal activity against bacteria (including spores), fungi and viruses. It has also been used to inactivate viruses during vaccine production. However, its use has been largely discontinued or restricted because it is classified as "reasonably anticipated to be a human carcinogen" by IARC; it can cause cancer following exposure[1][2][3][6]. Its mechanism of action involves alkylation of biological macromolecules such as DNA and proteins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propiolactone.